{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:29:12Z","timestamp":1794047352907,"version":"4.8.0"},"reference-count":29,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"3","license":[{"start":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T00:00:00Z","timestamp":1585785600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Next-generation sequencing (NGS) is used to investigate the presence of somatic mutations. The utility of incorporating routine sequencing to guide diagnosis and therapeutic decisions remains unclear. We report the findings of an observational, multicenter study that aimed to assess the impact of somatic mutation testing by NGS in a reallife setting of chronic myeloid malignancies. A total of 177 patients were enrolled, partitioned into two overlapping groups. In group A (n=94), the indication was to search for clonal hematopoiesis, in a context of suspected myelodysplastic syndrome or myeloproliferative neoplasia. In group B (n=95), the theranostic impact of somatic mutations was studied. A panel of 34 genes was used on DNA extracted from blood or bone marrow samples. Within group A, the detection of clonal hematopoiesis supported the diagnosis of chronic myeloid malignancies for 31 patients while the absence of clonal hematopoiesis ruled out the suspected diagnosis in 47 patients. Within group B, NGS identified prognostically relevant somatic mutations in 32 patients, which had a therapeutic impact in 18 cases. By determining the presence or absence of somatic mutations, the application of NGS in daily practice was found to be useful for an integrated final diagnosis in 83% of the patients. Moreover, the search for somatic mutations had a prognostic impact that led to treatment modification in 19% of the cases. This study outlines the fact that adequate implementation of new investigations may have a significant positive medico-economic impact by enabling appropriate management of patients.<\/jats:p>","DOI":"10.3324\/haematol.2019.242677","type":"journal-article","created":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T14:39:26Z","timestamp":1585838366000},"page":"701-707","source":"Crossref","is-referenced-by-count":8,"title":["Diagnosis and prognosis are supported by integrated assessment of next-generation sequencing in chronic myeloid malignancies. A real-life study"],"prefix":"10.3324","volume":"106","author":[{"family":"Sophie Vantyghem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Pierre Peterlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Sylvain Th\u00e9pot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Audrey M\u00e9nard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Viviane Dubruille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Camille Debord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Thierry Guillaume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Alice Garnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Amandine Le Bourgeois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Soraya Wuilleme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Catherine Godon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Olivier Theisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Marion Eveillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Jacques Delaunay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Herv\u00e9 Maisonneuve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Nadine Morineau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Bruno Villemagne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"St\u00e9phane Vigouroux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Fran\u00e7ois Subiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Elsa Lestang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Marion Loirat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Anne Parcelier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Pascal Godmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"M\u00e9lanie Mercier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Adrien Trebouet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Damien Luque Paz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Ronan Le Calloch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Lenaig Le Clech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"C\u00e9line Bossard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Anne Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Val\u00e9rie Ugo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Mathilde Hunault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Philippe Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Steven Le Gouill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Patrice Chevallier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Marie C. B\u00e9n\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Yannick Le Bris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2020,4,2]]},"reference":[{"key":"22096","doi-asserted-by":"crossref","unstructured":"Papaemmanuil E, Gerstung M, Malcovati L. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013; 122(22):3616-3627.","DOI":"10.1182\/blood-2013-08-518886"},{"key":"22097","doi-asserted-by":"crossref","unstructured":"Patel BJ, Przychodzen B, Thota S. Genomic determinants of chronic myelomonocytic leukemia. Leukemia. 2017; 31(12):2815-2823.","DOI":"10.1038\/leu.2017.164"},{"key":"22098","doi-asserted-by":"crossref","unstructured":"Grinfeld J, Nangalia J, Baxter EJ. Classification and personalized prognosis in myeloproliferative neoplasms. N Engl J Med. 2018; 379(15):1416-1430.","DOI":"10.1056\/NEJMoa1716614"},{"key":"22099","doi-asserted-by":"crossref","unstructured":"Valent P, Orazi A, Steensma DP. Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions. Oncotarget. 2017; 8(43):73483-73500.","DOI":"10.18632\/oncotarget.19008"},{"key":"22100","doi-asserted-by":"crossref","unstructured":"Malcovati L, Gall\u00ec A, Travaglino E. Clinical significance of somatic mutation in unexplained blood cytopenia. Blood. 2017; 129(25):3371-3378.","DOI":"10.1182\/blood-2017-01-763425"},{"key":"22101","doi-asserted-by":"crossref","unstructured":"Bejar R, Stevenson K, Abdel-Wahab O. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011; 364(26):2496-2506.","DOI":"10.1056\/NEJMoa1013343"},{"key":"22102","doi-asserted-by":"crossref","unstructured":"Greenberg PL, Tuechler H, Schanz J. Revised International Prognostic Scoring System for myelodysplastic syndromes. Blood. 2012; 120(12):2454-2465.","DOI":"10.1182\/blood-2012-03-420489"},{"key":"22103","doi-asserted-by":"crossref","unstructured":"Itzykson R, Kosmider O, Renneville A. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol. 2013; 31(19):2428-2436.","DOI":"10.1200\/JCO.2012.47.3314"},{"key":"22104","doi-asserted-by":"crossref","unstructured":"Passamonti F, Cervantes F, Vannucchi AM. A Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. Blood. 2010; 116(15):2857-2858.","DOI":"10.1182\/blood-2010-06-293415"},{"key":"22105","doi-asserted-by":"crossref","unstructured":"Guglielmelli P, Lasho TL, Rotunno G. MIPSS70: mutation-enhanced international prognostic score system for transplantation- age patients with primary myelofibrosis. J Clin Oncol. 2018; 36(4):310-318.","DOI":"10.1200\/JCO.2017.76.4886"},{"key":"22106","doi-asserted-by":"crossref","unstructured":"Bejar R, Steensma DP. Recent developments in myelodysplastic syndromes. Blood. 2014; 124(18):2793-2803.","DOI":"10.1182\/blood-2014-04-522136"},{"key":"22107","unstructured":"Publisher Full Text|"},{"key":"22108","doi-asserted-by":"crossref","unstructured":"Li MM, Datto M, Duncavage EJ. Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn. 2017; 19(1):4-23.","DOI":"10.1016\/j.jmoldx.2016.10.002"},{"key":"22109","doi-asserted-by":"crossref","unstructured":"Valent P, Horny HP, Bennett JM. Definitions and standards in the prognosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res. 2007; 31(6):727-736.","DOI":"10.1016\/j.leukres.2006.11.009"},{"key":"22110","unstructured":"Swerdlow SH. International Agency for Research on Cancer. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 2017."},{"key":"22111","doi-asserted-by":"crossref","unstructured":"Stanley N, Olson TS, Babushok DV. Recent advances in understanding clonal haematopoiesis in aplastic anaemia. Br J Haematol. 2017; 177(4):509-525.","DOI":"10.1111\/bjh.14510"},{"key":"22112","doi-asserted-by":"crossref","unstructured":"Such E, Germing U, Malcovati L. Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. Blood. 2013; 121(15):3005-3015.","DOI":"10.1182\/blood-2012-08-452938"},{"key":"22113","doi-asserted-by":"crossref","unstructured":"Passamonti F, Giorgino T, Mora B. A clinical-molecular prognostic model to predict survival in patients with post-polycythemia vera and post essential thrombocythemia myelofibrosis. Leukemia. 2017; 31(12):2726-2731.","DOI":"10.1038\/leu.2017.169"},{"key":"22114","doi-asserted-by":"crossref","unstructured":"Malcovati L, Papaemmanuil E, Bowen DT. for the Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium and of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic\/myeloproliferative neoplasms. Blood. 2011; 118(24):6239-6246.","DOI":"10.1182\/blood-2011-09-377275"},{"key":"22115","doi-asserted-by":"crossref","unstructured":"Elena C, Gall\u00ec A, Such E. Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. Blood. 2016; 128(10):1408-1417.","DOI":"10.1182\/blood-2016-05-714030"},{"key":"22116","doi-asserted-by":"crossref","unstructured":"Vannucchi AM, Lasho TL, Guglielmelli P. Mutations and prognosis in primary myelofibrosis. Leukemia. 2013; 27(9):1861-1869.","DOI":"10.1038\/leu.2013.119"},{"key":"22117","doi-asserted-by":"crossref","unstructured":"Kulasekararaj AG, Jiang J, Smith AE. Somatic mutations identify a subgroup of aplastic anemia patients who progress to myelodysplastic syndrome. Blood. 2014; 124(17):2698-2704.","DOI":"10.1182\/blood-2014-05-574889"},{"key":"22118","doi-asserted-by":"crossref","unstructured":"Yoshizato T, Dumitriu B, Hosokawa K. Somatic mutations and clonal hematopoiesis in aplastic anemia. N Engl J Med. 2015; 373(1):35-47.","DOI":"10.1056\/NEJMoa1414799"},{"key":"22119","doi-asserted-by":"crossref","unstructured":"Garrison LP, Neumann PJ, Erickson P, Marshall D, Mullins CD. Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report. Value Health. 2007; 10(5):326-335.","DOI":"10.1111\/j.1524-4733.2007.00186.x"},{"key":"22120","doi-asserted-by":"crossref","unstructured":"Genovese G, K\u00e4hler AK, Handsaker RE. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014; 371(26):2477-2487.","DOI":"10.1056\/NEJMoa1409405"},{"key":"22121","doi-asserted-by":"crossref","unstructured":"Steensma DP, Bejar R, Jaiswal S. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood. 2015; 126(1):9-16.","DOI":"10.1182\/blood-2015-03-631747"},{"key":"22122","doi-asserted-by":"crossref","unstructured":"Cargo CA, Rowbotham N, Evans PA. Targeted sequencing identifies patients with preclinical MDS at high risk of disease progression. Blood. 2015; 126(21):2362-2365.","DOI":"10.1182\/blood-2015-08-663237"},{"key":"22123","doi-asserted-by":"crossref","unstructured":"Malcovati L, Papaemmanuil E, Ambaglio I. Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia. Blood. 2014; 124(9):1513-1521.","DOI":"10.1182\/blood-2014-03-560227"},{"key":"22124","doi-asserted-by":"crossref","unstructured":"Nazha A, Narkhede MS, Radivoyevitch T. The Revised International Prognostic Scoring System \u201cMolecular\u201d (IPSS-Rm), a validated and dynamic model in treated patients with myelodysplastic syndromes (MDS). Blood. 2015; 126(23):607.","DOI":"10.1182\/blood.V126.23.607.607"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/9704\/70733","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/9704\/70734","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/9704\/70733","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T09:56:41Z","timestamp":1794045401000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/9704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,2]]},"references-count":29,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2019.242677","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4,2]]}}}